Tone mix
Week by week 52 weeks
Share of Summit Therapeutics Inc. Common Stock's 158 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Mar 16, 2026 · tone -100Summit Therapeutics (NASDAQ:SMMT) Downgraded by Jefferies Financial Group to "Hold"-145
- Week of Sep 29, 2025 · tone +99H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones+111
- Week of May 11, 2026 · tone -99H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT)-110
- Week of Aug 3, 2026 · tone +95Jim Cramer Stock Picks: Summit Therapeutics Is A 'Great Spec' - Carvana (NYSE:CVNA)+84
- Week of Feb 23, 2026 · tone -25HC Wainwright Cuts Summit Therapeutics (NASDAQ:SMMT) Price Target to $30.00-81
- Week of Nov 10, 2025 · tone +100Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial+81
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Summit Therapeutics Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 5 | +99 |
| Last 30 sessions | 23 | +78 |
| Last 90 sessions | 44 | +60 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
3 headlines, average tone +99: 3 positive, 0 neutral and 0 negative. Showing all 3.
- balticbusinessnews.com · 4 outletsLunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentPositive
- seekingalpha.com · 1 outletSummit Therapeutics reports survival benefit for cancer drug in trial (SMMT:NASDAQ)Positive
- www.finanznachrichten.de · 1 outletSummit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaPositive
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development | balticbusinessnews.com | 4 | Positive |
| Summit Therapeutics reports survival benefit for cancer drug in trial (SMMT:NASDAQ) | seekingalpha.com | 1 | Positive |
| Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
1 headline, average tone +98: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletAkeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract CancerPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 21, 2026
1 headline, average tone +96: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.finanznachrichten.de · 1 outletSummit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract CancerPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | www.finanznachrichten.de | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 20, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.rttnews.com · 1 outletSummit Therapeutics Stock Rises 7% Over Initiation Of Global Phase II Study Of IvonescimabPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Summit Therapeutics Stock Rises 7% Over Initiation Of Global Phase II Study Of Ivonescimab | www.rttnews.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletSummit Therapeutics PLC (NASDAQ:SMMT) Stock Has Average Price Target of $28.61Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Summit Therapeutics PLC (NASDAQ:SMMT) Stock Has Average Price Target of $28.61 | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Summit Therapeutics Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.